in this issue
Chemical Week Magazine :: Business & Finance :: Europe/Mideast
DSM Sets Ambitious Targets, Divests Citric Acid Business
8:52 AM MDT | September 24, 2010 | Natasha Alperowicz
DSM (Heerlen, the Netherlands) has updated financial targets to include sharply higher Ebitda and higher return on capital. The company also announced the sale of its citric acid business to Adcuram (Munich) and the formation of a joint venture with DuPont in surgical biomedical materials. DSM also plans to expand its biopharmaceutical joint venture with Crucell and is seeking partnerships for its anti-infectives business with companies in China and India. The company has set an Ebitda target of â‚¬1.4 billion-â‚¬1.6 billion ($1.9 billion-$2.1 billion) and return...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee